Sentinel lymph node biopsy for breast cancer: Current controversies

Breast Journal

Volumn 12, Issue SUPPL. 2, 2006, Pages

  Ozmen, V ^a,c   Cabioglu, N ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Haseki Education and Training Hospital   (Turkey)

^c NONE   (Turkey)

Author keywords

Breast cancer; DCIS; Internal mammary node; Lymphoscintigraphy; Sentinel lymph node biopsy; Staging

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOSCINTIGRAPHY; MICROMETASTASIS; MORBIDITY; PATIENT SELECTION; SENTINEL LYMPH NODE BIOPSY;

BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIONUCLIDE IMAGING; SENTINEL LYMPH NODE BIOPSY;

EID: 33748367220     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2006.00327.x     Document Type: Article

References (93)

1. Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-40.
2. Giuliano AE, Kigram DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
3. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-53.
4. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. A follow-up study of 4008 procedures. Ann Surg 2004;240:462-71.
5. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastasis. Prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005;241:152-58.
6. Veronesi U, Galimberti V, Mariani L, et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005;41:231-37.
7. Jeruss JS, Winchester DJ, Sener SF, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 2005;12:34-40.
8. Kokke MC, Jannink I, Barneveld PC, et al. Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study. Eur J Surg Oncol 2005;31:221-25.
9. Edge SB, Niland JC, Bookman MA, et al. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 2003;20:1514-21.
10. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005;23:4312-21.
11. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2005;15:1-15.
12. Ross MI. Sentinel node dissection in early-stage breast cancer: ongoing prospective randomized trials in the USA. Ann Surg Oncol 2001;8(9 suppl):77-81.
13. Krag DN, Julian TB, Harlow SP, et al. NSABP-32: phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann Surg Oncol 2004;11:208S-10S.
14. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
15. Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997;3:336-40.
16. Krag DN, Harlow S, Weaver D, Ashikaga T. Radiolabeled sentinel node biopsy: collaborative trial with the National Cancer Institute. World J Surg 2001;25:823-28.
17. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
18. McMasters KM, Tutle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-66.
19. Ozmen V, Muslumanoglu M, Cabioglu N, et al. Increased false negative rates in sentinel lymph node biopsies in patients with multifocal breast cancer. Breast Cancer Res Treat 2002;76:237-44.
20. Ross MI, Hunt KK. Role for lymphatic mapping and sentinel node biopsy in the management of early stage breast cancer. In: Singletary SE, ed. Breast Cancer. Berlin: Springer Verlag, 1999:171-83.
21. D'Eredita G, Ferrarese F, Cecere V, Massa ST, Carne F, Gennaro F. Subareolar injection may be more accurate than other techniques for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol 2003;10:942-47.
22. Layeeque R, Henry-Tillman R, Korourian S, Kass R, Klimberg VS. Subareolar sentinel node biopsy for multiple cancers. Am J Surg 2003;186:730-36.
23. Reitsamer R, Peintinger F, Rettenbacher L, Prokop E, Sedlmayer F. Subareolar subcutaneous injection of blue dye versus peritumoral injection of technetium-labeled human albumin to identify sentinel lymph nodes in breast cancer patients. World J Surg 2003;27:1291-94.
24. Eroglu A, Mudun A, Ozmen V, et al. Comparison of subdermal and peritumoral injection techniques of lymphoscintigraphy to determine the sentinel lymph node in breast cancer. Clin Nucl Med 2004;29:306-11.
25. Kelley MC, Hansen N, McMasters KM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg 2004;188:49-61.
26. Solorzano CC, Ross MI, Delpassand E, et al. Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol 2001;8:821-27.
27. 99mTc-labeled sulfur colloid the day before operation for breast cancer sentinel lymph node mapping is as successful as injection the day of operation. Am J Surg 2004;188:685-89.
28. Linehan DC, Hill AD, Tran KN, et al. Sentinel lymph node biopsy in breast cancer: unfiltered radioisotope is superior to filtered. J Am Coll Surg 1999;188:377-81.
29. Newman LA. Lymphatic mapping and sentinel lymph node biopsy in breast cancer patients: a comprehensive review of variations in performance and technique. J Am Coll Surg 2004;199:804-16.
30. Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002;95:385-88.
31. Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 2005;104:692-99.
32. Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol 2003;10:242-47.
33. Blessing WD, Stolier AJ, Teng SC, et al. A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. Am J Surg 2002;184:341-45.
34. Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg 2005;189:236-39.
35. Burak W, Walker MJ, Yee LD, et al. Routine lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer. Am J Surg 1999;177:445-49.
36. McMasters KM, Wong SL, Tutle TM, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 2000;231:724-31.
37. Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275-83.
38. Goyal A, Newcombe RG, Mansel RE, ALMANAC Trialist Group. Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for breast cancer. Eur J Cancer 2005;41:238-43.
39. Chagpar AB, Kehdy F, Scoggins CR, et al. Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer. Am J Surg 2005;190:557-62.
40. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
41. Klauber-DeMore N, Bevilacqua JLB, Van Zee KJ, Borgen P, Cody HS III. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 2001;193:547-55.
42. Galimberti V, Veronesi P, Arnone P, et al. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer. Ann Surg Oncol 2002;9:924-28.
43. Estourgie SH, Tanis PJ, Nieweg OE, Olmos RAV, Rutgers EJT, Kroon BBR. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol 2003;10:935-41.
44. Noguchi M. Current controversies concerning sentinel lymph node biopsy for breast cancer. Breast Cancer Res Treat 2004;84:261-71.
45. Kuerer HM, Newman LA. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol 2005;23:1689-705.
46. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-20.
47. Stearns V, Ewing CA, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9:235-42.
48. Fisher B, Wolmark N, Bauer M, et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-72.
49. Specht MC, Fey JV, Borgen PI, Cody HS. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg 2005;200:10-14.
50. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-86.
51. Julian TB, Patel N, Dusi D, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001;182:407-10.
52. Haid A, Tausch C, Lang A, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with invasive breast carcinoma? Cancer 2001;92:1080-84.
53. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin N Am 2003;83:931-42.
54. Balch GC, Mithani SK, Richards KR, Beauchamp D, Kelley MC. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 2003;10:616-21.
55. Kang SH, Kim S, Kwon Y, et al. Decreased identification rate of sentinel lymph node after neoadjuvant chemotherapy. World J Surg 2004;28:1019-24.
56. Jones JL, Zabicki K, Christian RL, et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 2005;190:517-20.
57. Sabel MS, Schott AF, Kleer CG, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003;186:102-5.
58. Schrenk P, Wayand W. Sentinel-node biopsy in axillary lymphnode staging for patients with multicentric breast cancer. Lancet 2001;357:122.
59. Fernandez K, Swanson M, Verbanac K, et al. Is sentinel lymphadenectomy accurate in multifocal and multicentric breast cancer. Ann Surg Oncol 2002;9:S16-S17.
60. Kumar R, Jana S, Heiba SI, et al. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer. J Nucl Med 2003;44:7-10.
61. Tousimis E, van Zee KJ, Fey JV, et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancer. J Am Coll Surg 2003;197:529-35.
62. Goyal A, Newcombe RG, Mansel RE, ALMANAC Trialist Group. Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur J Surg Oncol 2004;30:475-79.
63. Silverstein MJ, Rosser RJ, Gierson ED, et al. Axillary lymph node dissection for intraductal breast carcinoma - is it indicated? Cancer 1987;59:1819-24.
64. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005;200:516-26.
65. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513-19.
66. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003;138:309-13.
67. Intra M, Zurrida S, Maffini F, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol 2003;10:1160-65.
68. McMasters KM. Sentinel lymph node biopsy for ductal carcinoma in situ. In: Singletary SE, Robb GL, Hortobagyi GN, eds. Diseases of the Breast. Hamilton, Ontario, Canada: BC Decker, 2004:300-304.
69. Haigh PI, Hansen NM, Qi K, et al. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 2000;7:21-27.
70. Chagpar AB, Martin RC, Scoggins CR, et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery 2005;138:56-63.
71. Martin RCG, Chagpar A, Scoggins CR, et al. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg 2005;241:1005-15.
72. Port ER, Fey J, Gemignani ML, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg 2002;195:167-72.
73. Cody HS 3rd, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Oncol Surg 2001;8:13-19.
74. Cox CE, Dupont E, Whitehead GF, et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J 2002;8:88-91.
75. Albo D, Ames FC, Hunt KK, Ross MI, Singletary SE, Kuerer HM. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat 2003;77:9-14.
76. Port ER, Fey JV, Cody HS III, Borgen PI. Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer 2001;91:319-23.
77. Goyal A, Horgan K, Kissin M, et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004;30:480-83.
78. Harlow SP, Krag DN, Julian TB, et al. Prerandomization surgical training for the NSABP-B32 trial - a randomization phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node negative breast cancer. Ann Surg 2005;241:48-54.
79. McMasters KM, Wong SL, Chao C, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 2001;234:292-99.
80. Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005;103:492-500.
81. Moore KH, Thaler HT, Tan LK, Borgen PI, Cody HS III. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer 2004;100:929-34.
82. Ozmen V, Karanlik H, Cabioglu N, et al. Factors predicting the sentinel and non-sentinel node metastases in breast cancer. Breast Cancer Res Treat 2006;95:1-6.
83. Kim T, Agboola O, Giuliano A, et al. Lymphatic mapping and sentinel lymph node sampling in early-stage breast cancer: a meta-analysis. Cancer, 2006;106:4-16.
84. Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients: a meta-analysis. Cancer 2003;98:2307-15.
85. Viale G, Maiorano E, Prurevi G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005;241:319-25.
86. Chu KU, Turner RR, Hansen NM, Brennan MB, Giuliano AE. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol 1999;6:756-61.
87. Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999;17:1720-26.
88. Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003;10:248-54.
89. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003;10:1140-51.
90. Kocsis L, Svebis M, Boross G, et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg 2004;70:1019-24.
91. Hunt KK, Hwang RF, Ross MI, et al. Validation of a breast cancer nomogram for predicting additional nodal metastases after positive sentinel node biopsy. Ann Surg Oncol 2005;12:S17.
92. Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 2005;190:543-50.
93. Cabioglu N, Yazici MS, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 2005;11:5686-93.